Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia (DESTINY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01804985
Recruitment Status : Unknown
Verified May 2017 by Professor Richard E Clark, University of Liverpool.
Recruitment status was:  Active, not recruiting
First Posted : March 5, 2013
Last Update Posted : May 4, 2017
Sponsor:
Collaborators:
Newcastle University
Imperial College London
University of Glasgow
Information provided by (Responsible Party):
Professor Richard E Clark, University of Liverpool

Brief Summary:
The purpose of this study is to investigate whether some patients with excellent responses to chronic myeloid leukaemia (CML) treatment are being overtreated, and can remain well on either a lower dose of treatment or without treatment at all. The dose of imatinib (Glivec), nilotinib (Tasigna) or dasatinib (Sprycel) treatment will initially be cut to half the standard dose for 12 months, and then treatment will be stopped completely for a further two years. The trial information will also help to develop a de-escalation and stopping strategy for future newly diagnosed CML patients in the next British national CML study (to be known as SPIRIT3).

Condition or disease Intervention/treatment Phase
Chronic Myeloid Leukaemia Drug: Imatinib Drug: nilotinib Drug: dasatinib Phase 2

Detailed Description:

The next definitive UK phase III trial in chronic myeloid leukaemia (CML) will be SPIRIT3, which will open shortly. This will incorporate a de-escalation and stopping strategy for patients who achieve excellent responses after at least 3 years of treatment with a tyrosine kinase inhibitor (TKI).

DESTINY is to act as a pilot for this strategy in SPIRIT3, by defining the proportion of patients that relapse during 12 months of TKI de-escalation followed by 24 months of cessation. DESTINY also includes scientific bolt-on studies, quality of life assessments and health economic evaluation.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 168 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Trial of De-escalation and Stopping Treatment in Chronic Myeloid Leukaemia Patients With Excellent Responses to Tyrosine Kinase Inhibitor Therapy
Study Start Date : December 2013
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : May 2018


Arm Intervention/treatment
Experimental: De-escalated Treatment
Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months
Drug: Imatinib
Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on imatinib, the dose should be decreased to 200mg daily;
Other Name: Glivec or Gleevec

Drug: nilotinib
Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. if on nilotinib to 200mg twice daily (which is half the standard dose for second line use, since it is anticipated that the vast majority of nilotinib entrants will be receiving 400mg twice daily because of prior imatinib intolerance);
Other Name: Tasigna

Drug: dasatinib
Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on dasatinib then to 50 mg daily.
Other Name: Sprycel




Primary Outcome Measures :
  1. • The proportion of patients who can first de-escalate their treatment (to half the standard dose of their TKI) for 12 months, and then stop treatment completely for a further 2 years, without losing MMR. [ Time Frame: 37months ]
    • The proportion of patients who can first de-escalate their treatment (to half the standard dose of their TKI) for 12 months, and then stop treatment completely for a further 2 years, without losing MMR.


Secondary Outcome Measures :
  1. • Proportion of patients who can successfully de-escalate their treatment (to half the standard dose of their TKI), but who then lose MMR on complete TKI cessation [ Time Frame: 37 months ]
    • Proportion of patients who can successfully de-escalate their treatment (to half the standard dose of their TKI), but who then lose MMR on complete TKI cessation

  2. • Proportion of patients who lose their MMR on de-escalation/stopping and regain MMR on resumption of their TKI [ Time Frame: 37 months ]
    • Proportion of patients who lose their MMR on de-escalation/stopping and regain MMR on resumption of their TKI

  3. • Quality of Life [ Time Frame: 37 months ]
    • Quality of Life

  4. • Health Economic Assessment [ Time Frame: 37 months ]
    • Health Economic Assessment

  5. • Lab studies to define subsets of patients who are more likely to relapse on de-escalation / cessation. [ Time Frame: 37 months ]
    • Lab studies to define subsets of patients who are more likely to relapse on de-escalation / cessation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. CML in first chronic phase.
  2. Demonstration of BCR-ABL1 positivity at/shortly after original diagnosis.
  3. Written Informed Consent
  4. Must have received TKI treatment for at least 3 years.
  5. At least 3 molecular results over the preceding 12 months, that fit either of the following groups (results from any UK lab are acceptable):

    • (MR4 group) all the available BCR-ABL1 molecular results over the preceding 12 months are in MR4 (MR4 is defined as a BCR-ABL1/ABL1 ratio of zero, (reported to International Standards (IS) where possible; with at least 10,000 ABL1 control transcripts).
    • (MMR group) some or all BCR-ABL1 molecular results are in major molecular response (MMR), defined here as a BCR-ABL1/ABL1 ratio of 0.1% or less, (reported to International Standard (IS) where possible), but not zero, with at least 10,000 ABL1 control transcripts. If the results over the preceding 12 months are a mix of MMR and undetectable BCR-ABL1, then the patient is eligible for the MMR but not the MR4 group.

Exclusion Criteria:

  1. Age under 18
  2. Life expectancy predicted to be less than 37 months because of intercurrent illness
  3. Presence of serious concomitant illness (e.g. heart, renal, respiratory or active malignant disease) that might preclude completion of the trial
  4. CML in accelerated phase or blast crisis at any time
  5. Any molecular result during the preceding 12 months that is not in either MMR or MR4.
  6. Patients who switched previous licensed TKI treatment (imatinib, nilotinib or dasatinib) twice or more because of intolerance
  7. Treatment with higher than standard TKI doses ('standard' is defined as imatinib 400mg daily, nilotinib 400mg twice daily or dasatinib 100mg daily). However, an exception is made for patients who at original diagnosis commenced on either 800mg of imatinib on the SPIRIT1 study, or 140mg (or 70mg b.d) of dasatinib in the Bristol-Myers Squibb 034 study. In each case these latter patients ARE eligible provided they fulfil other molecular criteria, since they do not demonstrate resistant disease.
  8. Patients who switched previous licensed TKI treatment (imatinib, nilotinib or dasatinib) because of resistance. Patients treated with lower (but at least 50%) than the standard TKI doses (as defined in previous criterion) for tolerance reasons may be included, but will de-escalate to the same doses as for standard dose patients and will be analysed separately, as they could be seen as undertreated.
  9. Previous treatment with ponatinib or bosutinib. Patients who received interferon prior to commencing TKI (even if resistant to their interferon) are eligible, provided their response to TKI fits the entry criteria.
  10. Pregnant or lactating women
  11. Women of childbearing potential (including women whose last menstrual period was less than one year prior to screening) who are unable or unwilling to use adequate contraception from study start to one year after the last dose of protocol therapy. Adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01804985


Locations
Layout table for location information
United Kingdom
University of Liveprool
Liverpool, United Kingdom, L69 3GL
Sponsors and Collaborators
University of Liverpool
Newcastle University
Imperial College London
University of Glasgow
Investigators
Layout table for investigator information
Principal Investigator: Richard E Clark, MA MD University of Liverpool

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Professor Richard E Clark, Consultant Haematologist, University of Liverpool
ClinicalTrials.gov Identifier: NCT01804985     History of Changes
Other Study ID Numbers: 4203
First Posted: March 5, 2013    Key Record Dates
Last Update Posted: May 4, 2017
Last Verified: May 2017

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Imatinib Mesylate
Dasatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action